The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone
S Dermime, S Afreen - Hematology/oncology and stem cell …, 2014 - journals.lww.com
Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been
linked to worse prognosis and resistance to anti-cancer therapies in several malignancies …
linked to worse prognosis and resistance to anti-cancer therapies in several malignancies …
[HTML][HTML] B7-H3, a checkpoint molecule, as a target for cancer immunotherapy
S Yang, W Wei, Q Zhao - International journal of biological …, 2020 - ncbi.nlm.nih.gov
Abstract B7-H3 (also known as CD276) is a newly found molecule of B7 family, which may
be a promising target for cancer treatment. B7-H3 protein was demonstrated to be …
be a promising target for cancer treatment. B7-H3 protein was demonstrated to be …
B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes
Purpose: The immune checkpoint PD-1 and its receptor B7-H1 (PD-L1) are successful
therapeutic targets in cancer but less is known about other B7 family members. Here, we …
therapeutic targets in cancer but less is known about other B7 family members. Here, we …
The role of B7-H3 in tumors and its potential in clinical application
R Feng, Y Chen, Y Liu, Q Zhou, W Zhang - International …, 2021 - Elsevier
Abstract B7-H3 (CD276 molecule) is an immune checkpoint from the B7 family of molecules
that acts more as a co-inhibitory molecule to promote tumor progression. It is abnormally …
that acts more as a co-inhibitory molecule to promote tumor progression. It is abnormally …
[HTML][HTML] B7-H3 role in the immune landscape of cancer
The field of immunotherapy is a continually expanding niche in cancer biology research. In
the last two decades, there has been significant progress in identifying better targets and …
the last two decades, there has been significant progress in identifying better targets and …
Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy
E Picarda, KC Ohaegbulam, X Zang - Clinical Cancer Research, 2016 - AACR
Abstract B7-H3 (CD276) is an important immune checkpoint member of the B7 and CD28
families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition …
families. Induced on antigen-presenting cells, B7-H3 plays an important role in the inhibition …
Clinical significance of B7-H1( PD-L1) expression in human acute leukemia
X Chen, S Liu, L Wang, WG Zhang, Y Ji… - Cancer biology & …, 2008 - Taylor & Francis
B7-H1 (B7 homologue 1, PD-L1), expressed on the surface of tumor cells or antigen-
presenting cells in the tumor microenvironment, can suppress antitumor immune reaction …
presenting cells in the tumor microenvironment, can suppress antitumor immune reaction …
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
L Van Der Kraak, G Goel, K Ramanan… - … for immunotherapy of …, 2016 - Springer
Background Resistance to chemotherapy is a major obstacle in the effective treatment of
cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an …
cancer patients. B7-homolog 1, also known as programmed death ligand-1 (PD-L1), is an …
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
B Zhao, H Li, Y Xia, Y Wang, Y Wang, Y Shi… - Journal of Hematology & …, 2022 - Springer
Immunotherapy for cancer is a rapidly developing treatment that modifies the immune
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …
system and enhances the antitumor immune response. B7-H3 (CD276), a member of the B7 …
[HTML][HTML] Overexpression of B7-H1 correlates with malignant cell proliferation in pancreatic cancer
X Song, J Liu, Y Lu, H Jin… - Oncology Reports, 2014 - spandidos-publications.com
Abstract B7-H1, a member of the B7 family of proteins, is hypothesised to play an important
role in the immune escape of tumours through its binding to the PD-1 receptor on activated T …
role in the immune escape of tumours through its binding to the PD-1 receptor on activated T …